CommercialCoverageHigh impact
Knee Braces (CPB 1094, reviewed 20-2026-01)
Aetna·Orthopedics, Physical Therapy, PM&R (Physical Medicine & Rehab) +2 more·DME
Effective date
Jan 20, 2026
We identified it
Aug 19, 2026
Summary
Aetna has updated CPB 1094 on knee braces (DME) effective immediately, establishing comprehensive medical necessity criteria for orthopedic knee braces including prefabricated and custom-made options. The policy specifies strict documentation requirements (objective joint laxity testing, not subjective pain), provider qualifications, and conditions under which braces are considered medically necessary versus experimental. Billing teams must ensure claims meet all documented criteria or face denials.
Action Required
By January 20, 2026 (or immediately for current claims): 1) Billing team must update claim submission protocols to require documentation of objective joint laxity testing (e.g., varus/valgus instability, anterior/posterior Drawer test) before approving knee brace claims—subjective pain documentation alone will result in denial. 2) Implement pre-authorization checklist requiring: provider qualification verification (ABC/BOC certification or state licensure), evidence of physical examination, and confirmation of service date within 6 months of prescription. 3) For codes L2385 and L2395 (heavy-duty knee joints), require weight documentation >300 lbs in claim. 4) For code L2755 (high-strength lightweight material), verify patient weight >250 lbs and confirm prefabricated brace was attempted first. 5) Update encounter forms and prior authorization templates to distinguish between medically necessary indications (listed conditions with objective findings) and experimental/investigational uses. 6) Train front desk and coding staff that knee braces for contracture must document passive ROM ≥10 degrees; post-operative/injury braces require prescription within 6 weeks; and custom-made braces require documentation of specific fitting contraindications. 7) Flag for denial any claims lacking objective examination findings or claims for non-listed indications. Failure to verify these criteria will result in claim denials under this policy.